ArticleBMC cancer2018

'DURVIT': a phase-I trial of single low-dose durvalumab (Medi4736) IntraTumourally injected in cervical cancer: safety, toxicity and effect on the primary tumour- and lymph node microenvironment.

J Rotman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.